Profile and risk factors of pre-XDR-TB and XDR-TB patients in a national reference hospital for Sumatra region of Indonesia
- PMID: 38455612
- PMCID: PMC10919437
- DOI: 10.52225/narra.v3i3.407
Profile and risk factors of pre-XDR-TB and XDR-TB patients in a national reference hospital for Sumatra region of Indonesia
Abstract
The low treatment rate, low treatment success rate and high mortality rate of patients with pre-extensively drug-resistant tuberculosis (pre-XDR-TB) and extensively drug-resistant TB (XDR-TB) need serious attention. The aim of this study was to describe the profiles of patients with pre-XDR-TB and XDR-TB cases and to determine associated risk factors of their incidence in Indonesia. A retrospective case-control study was conducted at H. Adam Malik General Hospital in Medan, North Sumatra of which all sensitive-drug TB (SD-TB), pre-XDR-TB, and XDR-TB patients aged 18 years or older treated between October 2019 to June 2022 were included. Chi-squared test or Kruskal Wallis test and multiple logistic regression were used to determine the risk factors associated with pre-XDR-TB and XDR-TB incidence. A total 16 patients of case group (15 pre-XDR-TB and one XDR-TB) and 116 SD-TB patients (control group) were included in the final analysis. Out of total patients within case group, 62.5% were male, 43.8% aged between 56-65 years, 62.5% graduated from high school or equivalent, and 25% were unemployed. The majority of patients had no comorbid (62.5%), had history of anti-TB treatment (93.8%), and had secondary resistance (93.8%). Multivariate analysis indicated that age (OR: 10.01; 95%CI: 1.49- 66.91, p=0.018) and previous history of anti-TB treatment (OR: 216.25; 95%CI: 18.62- 2511.60, p<0.001) were significantly associated with incidence of pre-XDR-TB and XDR-TB. This study highlights that having previous history of anti-TB treatment and older age are the predictors of the incidence of pre-XDR-TB and XDR-TB.
Keywords: Tuberculosis; XDR-TB; drug resistant-tuberculosis; pre-XDR-TB; risk factor.
© 2023 The Author(s).
Conflict of interest statement
The authors declare that there is no conflict of interest.
Figures
Similar articles
-
Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases.Microbiol Spectr. 2024 May 2;12(5):e0277023. doi: 10.1128/spectrum.02770-23. Epub 2024 Apr 10. Microbiol Spectr. 2024. PMID: 38597637 Free PMC article.
-
High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.Genome Med. 2022 Aug 22;14(1):95. doi: 10.1186/s13073-022-01076-0. Genome Med. 2022. PMID: 35989319 Free PMC article.
-
[Pre-extensively and extensively drug-resistant tuberculosis, in Libreville, Gabon].Rev Mal Respir. 2024 Oct;41(8):542-548. doi: 10.1016/j.rmr.2024.06.011. Epub 2024 Aug 22. Rev Mal Respir. 2024. PMID: 39179426 French.
-
Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis.Int J Infect Dis. 2023 Jul;132:50-63. doi: 10.1016/j.ijid.2023.04.392. Epub 2023 Apr 16. Int J Infect Dis. 2023. PMID: 37072053 Free PMC article.
-
Trends in drug-resistant tuberculosis in China: data from a clinical tuberculosis centre.Int J Tuberc Lung Dis. 2017 Sep 1;21(9):990-995. doi: 10.5588/ijtld.17.0086. Int J Tuberc Lung Dis. 2017. PMID: 28826447 Review.
Cited by
-
Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan.IJTLD Open. 2024 Sep 1;1(9):391-397. doi: 10.5588/ijtldopen.24.0351. eCollection 2024 Sep. IJTLD Open. 2024. PMID: 39301133 Free PMC article.
-
Risk factors of pulmonary tuberculosis in Indonesia: A case-control study in a high disease prevalence region.Narra J. 2024 Aug;4(2):e943. doi: 10.52225/narra.v4i2.943. Epub 2024 Aug 6. Narra J. 2024. PMID: 39280301 Free PMC article.
References
-
- World Health Organization. WHO announces updated definitions of extensively drug-resistant tuberculosis. Available from: https://www.who.int/news/item/27-01-2021-who-announces-updated-definitio... nt-tuberculosis. Accessed: 13 September 2021.
-
- World Health Organization. Global tuberculosis report 2021. Geneva. 2021.
-
- Heyckendorf J, Van-Leth F, Avsar K, et al. . Treatment responses in multidrug-resistant tuberculosis in Germany. Int J Tuberc Lung Dis 2018;22(4):399–406. - PubMed
-
- Pasechnik OA, Zimoglyad AA, Yarusova IV, et al. . Prevalence of extensively drug-resistant tuberculosis: A descriptive study. Epidemiol Vaccinal Prev 2018;17(4):13–19.
LinkOut - more resources
Full Text Sources